SciSparc Shares Are Trading Higher After the Company Announced It Signed an Exclusive Patent License Agreement With Polyrizon for the Out-licensing of Its SCI-160 Program for the Treatment of Pain.
SciSparc Shares Are Trading Higher After the Company Announced It Signed an Exclusive Patent License Agreement With Polyrizon for the Out-licensing of Its SCI-160 Program for the Treatment of Pain.
SciSparc股份正在交易，公司宣佈與Polyrizon簽訂獨家專利許可協議，將其SCI-160方案進行外部許可以治療疼痛。
SciSparc Shares Are Trading Higher After the Company Announced It Signed an Exclusive Patent License Agreement With Polyrizon for the Out-licensing of Its SCI-160 Program for the Treatment of Pain.
SciSparc股份正在交易，公司宣佈與Polyrizon簽訂獨家專利許可協議，將其SCI-160方案進行外部許可以治療疼痛。